

REMARKS/ARGUMENTS

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension of one month of the period for response to the Office Action. The enclosed cheque includes the prescribed fee.

The Examiner indicated that SEQ ID No: 8 apparently is sequential in the 3' to 5' direction and is no listed in the Sequence Listing, contrary to 37 CFR 1.822(j). This is incorrect. The nucleic acid sequence represented by SEQ ID No: 8 is correctly shown in the 5' to 3' direction. No substitute Sequence Listing is required.

The SEQ ID No: 8 sequence is used in the 3' to 5' direction in the assembly procedure illustrated in Figure 2B. As may be seen from the enclosed representation of the sequences in colour, the reverse of SEQ ID No: 8 (CTLB36.2) overlaps with the 3' end of SEQ ID No: 7 (CTLB36.1) and the 5' end of SEQ ID No: 9 (CTLB36.3). It is submitted that this is quite clear from the sequences provided for CTLB36.1, CTLB36.2 and CTLB36.3 provided in Figure 2C and the schematic of Figure 2B.

For clarification, the description on page 22 has been amended to refer to use of CTLB36.2 in the reverse direction to that shown in Figure 2C.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

It is believed that this application is now in condition for allowance and early and favourable consideration and allowance are respectfully solicited.

Respectfully submitted,



Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada,
(416) 595-1155
FAX No. (416) 595-1163

Appl. No. 09/007,093

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Disclosure:

Please replace the paragraph beginning at page 22, line 12, with the following rewritten paragraph:

The oligonucleotides CLTB36.1, CLTB36.2 (used in the reverse direction of SEQ ID No: 8), and CLTB36.3 were mixed together (30 pm each) in PCR reaction buffer heated up to 90°C and slowly annealed at about 45°C. Subsequently the volume was made up to 100 μ l by adequate additions of buffer, dNTP's primers (PrLC.F and PrR for light chain antigen; PrHC.F and Pr.R for heavy chain antigen; 100 pmol each) using material and protocols from a Gene Amp PCR kit and a PCR reaction was performed. The aqueous phase of the reaction mixture was removed to another tube and an aliquot (5 μ l) was ligated into pCRII vector and cloned using a 'TA cloning kit' (Invitrogen). The insert was sequenced and clones containing the correct sequence excisable by the correct combination of restriction sites were established.

From Figure 2C

CLTB36.1

5' CATTATGGATCCGGTCCTAAAGAACCTTTAGAGACTATGTTGATAGGTTTATAA
GAAT 3' SEQ ID 7

CLTB36.2

5' GCCCTACCAGGCCCTATATGTATCCTCTCCTCTTATTCTTATAAAACCTA 3' SEQ
ID 8

Reverse

3' ATCCAAAATATTCTTATTCTCCTCTCCTATGTATATCCGGACCATCCCG 5'

Reverse compliment

3' TAGGTTTATAAGAATAAGAGGAAGAGGATACATATAGGGCCTGGTAGGGC 5'

CLTB36.3

5' AGGGCCTGGTAGGGCTTTTATACTACTAAGAATTAATAAAAGCTTAGCG 3' SEQ
ID 9

CTLB36.1

5' CATTATGGATCGGGTCCCTAAAGAACCTTTAGAGACTATGTTGATAGGTTTATAAGAT
3' ATCCAAAAATATTCTTAT
3' CTTLB36 2 reverse

363

3' CTCGCGGCTGGTAGGGCTTTTAACTACTAAGAATTAAAGCTTGA
5' TCCCGGGACATCCG